Galderma S.a.

Galderma Research & Development

Galderma Laboratories Inc.

Philippe Andres

Yin-Ku Lin

Antoine Charles Bily

Isabelle Cardinaud

Jean-Thomas Pierson

Loïc Le Bronec

Johannes Voegel

Sandrine Rethore

Itaru Suzuki

Philippe Martel

Arthur Clapp

Mario Lacouture

Warren J Scherer

A method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects, is described. In particular, the beneficial effects are achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.

Methods and compositions for reducing side effects in chemotherapeutic treatments

A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

Pharmaceutical composition comprising refined indigo naturalis extracts and the use thereof

The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.

Extract from Indigo Naturalis and a process for preparing the same

A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting, including methicillin-resistant. A method of inhibiting, including methicillin-resistant, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.

Antibacterial indigo naturalis or indigo-producing plant extract and use thereof

Pharmaceutical composition comprising refinedextracts and the use thereof

Extract from indigo naturalis and a process for preparing the same

A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.

Method of reducing hair loss associated with chemotherapy

Pharmaceutical composition comprising refined indigo naturalis extract and the use thereof

A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.

Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract

The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.

Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.

Growing community of inventors

Peymeinade, France

Philippe Andres